Stay updated on Sitravatinib Combo in Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo in Advanced NSCLC Clinical Trial page.

Latest updates to the Sitravatinib Combo in Advanced NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoChange DetectedThe webpage has updated the reporting dates for study results and clarified the definitions of key endpoints such as Objective Response Rate (ORR), Overall Survival (OS), and Progression Free Survival (PFS). Additionally, the number of participants experiencing adverse events is now included in the study's safety analysis.SummaryDifference8%
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new version of the study, including the addition of collaborators and a principal investigator, while significant details about the study's design and objectives have been removed.SummaryDifference46%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Sitravatinib Combo in Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo in Advanced NSCLC Clinical Trial page.